

This type of analysis brings information that may suggest a recent passage through the disease.
When the human body is infected with SARS-CoV-2, the virus fools immune system and enters cells by binding through its Spike Proteins to ACE2 cellular receptors. Following infection, the body develops many types of antibodies, including Anti Protein N Antibodies (nucleocapsid - protein that contains viral RNA - the most abundant protein in the virus) and Anti Protein-Spike antibodies - RBD (Receptor Binding Domain in the S1 domain of Spike protein).
This type of analysis brings information that may suggest a recent passage through the disease.
When the human body is infected with SARS-CoV-2, the virus fools immune system and enters cells by binding through its Spike Proteins to ACE2 cellular receptors. Following infection, the body develops many types of antibodies, including Anti Protein N Antibodies (nucleocapsid - protein that contains viral RNA - the most abundant protein in the virus) and Anti Protein-Spike antibodies - RBD (Receptor Binding Domain in the S1 domain of Spike protein).
This type of analysis brings information that may suggest a recent passage through disease.
When the human body is infected with SARS-CoV-2, the virus fools immune system and enters cells by binding through its Spike Proteins to ACE2 cellular receptors. Following infection, the body develops many types of antibodies, including Anti Protein N Antibodies (nucleocapsid - protein that contains viral RNA - the most abundant protein in the virus) and Anti Protein-Spike antibodies - RBD (Receptor Binding Domain in the S1 domain of Spike protein).
- Anti Protein N antibodies are developed only after going through disease, NOT through vaccination.
- Spike Anti Protein Antibodies (RBD S1) are developed both after going through disease but also after vaccination.
- IgM and IgG blood tests are not diagnostic and should be interpreted in a clinical context by your doctor.